Gorelick, Alexander N. http://orcid.org/0000-0001-6736-8246
Sánchez-Rivera, Francisco J. http://orcid.org/0000-0002-8466-8563
Cai, Yanyan
Bielski, Craig M.
Biederstedt, Evan
Jonsson, Philip
Richards, Allison L.
Vasan, Neil http://orcid.org/0000-0003-1779-484X
Penson, Alexander V.
Friedman, Noah D.
Ho, Yu-Jui
Baslan, Timour
Bandlamudi, Chaitanya
Scaltriti, Maurizio http://orcid.org/0000-0002-5522-1447
Schultz, Nikolaus
Lowe, Scott W. http://orcid.org/0000-0002-5284-9650
Reznik, Ed http://orcid.org/0000-0002-6511-5947
Taylor, Barry S. http://orcid.org/0000-0002-3355-9471
Article History
Received: 7 September 2019
Accepted: 6 April 2020
First Online: 27 May 2020
Competing interests
: N.V. reports advisory board activities for Novartis and consulting activities for Petra Pharmaceuticals. M.S. has received research funding from Puma Biotechnology, Daiichi-Sankio, Immunomedics, Targimmune and Menarini Ricerche; is a cofounder of Medendi.org, and is on the advisory boards of the Bioscience Institute and Menarini Ricerche. S.W.L. is a founder and scientific advisory board member of Oric Pharmaceuticals, Mirimus, Inc. and Blueprint Medicines; and is on the scientific advisory boards of Constellation Pharmaceuticals, Petra Pharmaceuticals and PMV Pharmaceuticals. B.S.T. reports receiving honoria and research funding from Genentech and Illumina, and advisory board activities for Boehringer Ingelheim and Loxo Oncology, a wholly owned subsidiary of Eli Lilly, Inc. All stated activities were outside of the work described here. The other authors declare no competing interests.